Urine Ammonium Concentrations and Cardiovascular and Kidney Outcomes in Systolic Blood Pressure Intervention Trial Participants with CKD

Author:

Bullen Alexander L.12ORCID,Katz Ronit3ORCID,Seegmiller Jesse4ORCID,Garimella Pranav S.2ORCID,Ascher Simon B.56ORCID,Rifkin Dena E.12ORCID,Raphael Kalani L.78ORCID,Shlipak Michael G.59ORCID,Ix Joachim H.12

Affiliation:

1. Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, California

2. Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California

3. Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington

4. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota

5. Kidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, California

6. Division of Hospital Medicine, University of California Davis, Sacramento, California

7. Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah

8. VA Salt Lake City Health Care System, Salt Lake City, Utah

9. Department of Medicine, San Francisco VA Medical Center, San Francisco, California

Abstract

Key Points Among nondiabetic individuals with hypertension and CKD, higher urine ammonium concentration is associated with higher risk of cardiovascular disease.Urine ammonium was not associated with all-cause mortality or CKD progression, AKI, or linear eGFR decline in the Systolic Blood Pressure Intervention Trial cohort. Background Impaired urine ammonium excretion is common in CKD and may identify risk of metabolic acidosis earlier than reductions in serum bicarbonate or pH and thus may have associations with cardiovascular disease (CVD) outcomes. We evaluated the association of urine ammonium with CVD and kidney outcomes among persons with hypertension and nondiabetic CKD enrolled in a trial of BP reduction. Methods We measured urine ammonium concentration in spot urine specimens collected at baseline among 2092 participants of the Systolic Blood Pressure Intervention Trial (SPRINT) with an eGFR <60 ml/min per 1.73 m2. We used multivariable-adjusted Cox models to evaluate associations of urine ammonium concentration with the SPRINT CVD composite outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or CVD death), all-cause mortality, the SPRINT kidney composite outcome (50% kidney function decline, ESKD, or transplant), and AKI. Results At baseline, the mean (SD) age was 73 (9) years; 40% were female; and 25% were Black participants. The mean (SD) serum bicarbonate was 25.6 (2.8) mmol/L, median (interquartile range) urine ammonium concentration was 14.4 (9.5–23.1) mmol/L, and median (interquartile range) eGFR was 49 (39–55) ml/min per 1.73 m2. There were 255 CVD composite events, 143 deaths, 63 kidney composite events, and 146 AKI events during a median follow-up of 3.8 years. In multivariable models, each two-fold higher urinary ammonium concentration was associated with a 26% (95% confidence interval, 1.05 to 1.52) higher risk of the CVD composite, whereas there was no association with all-cause mortality, the SPRINT kidney composite outcome, or AKI. Conclusions Among nondiabetic individuals with hypertension and CKD, higher urine ammonium concentration is associated with higher risk of CVD. Further studies are needed to evaluate this association in other cohorts.

Funder

US Department of Veterans Affairs

National Institute of Diabetes and Digestive and Kidney Diseases

American Heart Association

Case Western Reserve University

Ohio State University

University of Pennsylvania

Boston University

Stanford University

Tufts University

University of Illinois System

University of Pittsburgh

University of Texas Southwestern

University of Utah

Vanderbilt University

George Washington University

University of California, Davis

University of Florida

University of Michigan

Tulane University

Wake Forest University

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference31 articles.

1. Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease;Raphael;Nephrology (Carlton).,2014

2. Metabolic acidosis and subclinical metabolic acidosis in CKD;Raphael;J Am Soc Nephrol.,2018

3. Effects of in vivo metabolic acidosis on midcortical bone ion composition;Bushinsky;Am J Physiol.,1999

4. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy;Mahajan;Kidney Int.,2010

5. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD;Kovesdy;Nephrol Dial Transplant.,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3